***Background.*** There are few data about the optimal drug regimen and duration of therapy for Bacillus Calmette-Guerein (BCG) osteitis.

***Methods.*** We searched Medline using terms: Mycobacterium bovis, immunization, BCG vaccine, osteitis, and bone diseases; infectious. Exclusion criteria were; non-English, single case report, intravesicular BCG, non-human subjects, and insufficient description of treatment and complications.

***Results.*** Our search yielded 66 studies, with 6 case series (n = 2-222), the cumulative total was 261 patients.

Median onset of BCG osteitis was 1 year post-vaccination (3-26 months). The lower extremity was the most common site. Most cases were immune-competent, however variations in the interferon-gamma receptor (n = 6), and mannose-binding lectin (n = 56) genotypes were found.

Surgical biopsy was performed in 255 cases, diagnosis was via culture in 135 cases, pathology in 227 and exclusively clinical/radiologic in 6. TB skin tests were positive in 95 cases.

The number of patients who underwent surgical debridement is unclear. Drug therapy usually included an early intensive phase of 2 months, followed by consolidation therapy for a total duration of 6-24 months. Drug combinations included INH, Rifampin, and a third drug, 13 cases received \<3 effective drugs. No definite association between duration, drug regimen, and complication rate could be discerned (table).

Complications occurred in 5%, including fistulae, abscess formation, and further surgical intervention, relapses occurred in 2%. The largest series reported complications in 3%.

###### 

Treatment modalities

  Case Series              n           Regimen (n)               Duration median (m)       Surgery (n) B = biopsy D = debridement  
  ---------------------- ----- ---------------------------- ----------------------------- ---------------------------------------- --------------
  **Kroger**              222   S + (EA or I) or S + I + R   I + (EA OR R) Followed by I                     12                     B or D (217)
  **Castro-Rodriguez**    10             I, R, P                        I, R                                6.5                        B or D
  **Bergdahl**            18             S, I, R                        I, R                                 7                           D
  **Karnak**               2               I, R                           6                                  D                     
  I                                                                                                                                
  **Al Jassir**            3            I, R, PAS                        12                                  D                     
  **Sasaki**               6              I (1)                          N/a                            D (2) B (3)                
  I, R, S ( 3)                                                                                                                     
  I, R, E (2)                                                                                                                      

m = month, S-Streptomycin, EA-Ethionamide, I-Isoniazid, R-Rifampin, P-Pyrazinamide, E-Ethambutol, PAS-Para-amino salicylic acid

***Conclusion.*** BCG osteitis is a rare complication with limited literature. Most patients respond well but the optimal therapy to prevent relapse and complications requires further study.
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